ARN-509 — Competitive Intelligence Brief

ARN-509 (ARN-509) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor inhibitor. Area: Oncology.

phase 2 Androgen receptor inhibitor Androgen receptor Oncology Small molecule

Target snapshot

ARN-509 (ARN-509) — Aragon Pharmaceuticals, Inc.. ARN-509 is an androgen receptor inhibitor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARN-509 TARGET	ARN-509	Aragon Pharmaceuticals, Inc.	phase 2	Androgen receptor inhibitor	Androgen receptor
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Nubeqa	darolutamide	Bayer	marketed		androgen receptor (AR)	2019-01-01
Erleada	apalutamide	Johnson & Johnson	marketed		Androgen receptor	2018-01-01
APALUTAMIDE	APALUTAMIDE		marketed		Androgen Receptor (AR)	2018-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor inhibitor class)

1. Aragon Pharmaceuticals, Inc. · 1 drug in this class
2. Arvinas Androgen Receptor, Inc. · 1 drug in this class
3. Astellas Pharma · 1 drug in this class
4. AstraZeneca · 1 drug in this class
5. City of Hope Medical Center · 1 drug in this class
6. Pfizer Inc. · 1 drug in this class
7. Tata Memorial Centre · 1 drug in this class
8. Triple Hair Inc · 1 drug in this class